Epion Therapeutics granted FDA Fast Track designation for EpiSmart corneal cross-linking | Optometry Times - Clinical News

In a trial involving more than 3,000 Chinese schoolchildren, researchers found that greater time outdoors protected hyperopic—but not premyopic—eyes from myopic progression. Smartwatch data revealed only modest benefit for premyopic children, even at high exposure levels, underscoring the need for earlier preventive measures and adjunctive strategies such as low-dose atropine or red-light therapy.